Validation of IKK<i>β</i> as therapeutic target in airway inflammatory disease by adenoviral‐mediated delivery of dominant‐negative IKK<i>β</i> to pulmonary epithelial cells
Matthew C. Catley, Joanna E. Chivers, Neil S. Holden, Peter J Barnes, Robert Newton (2005). Validation of IKK<i>β</i> as therapeutic target in airway inflammatory disease by adenoviral‐mediated delivery of dominant‐negative IKK<i>β</i> to pulmonary epithelial cells. , 145(1), DOI: https://doi.org/10.1038/sj.bjp.0706170.
